Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
Zhonghua Yi Xue Za Zhi ; 103(12): 924-926, 2023 Mar 28.
Article in Chinese | MEDLINE | ID: mdl-36973221

ABSTRACT

Objective: To evaluate the efficacy of ketochromate tromethamine and phloroglucinol combination therapy in early expulsion of ureteral calculi after extracorporeal shockwave lithotripsy (ESWL) in patients with distal ureteral clculi. The clinical and follow-up data of 275 patients with lower ureteral calculi who underwent ESWL were collected retrospectively in Civil Aviation General Hospital from January 1st 2021 to June 30th 2021. According to whether adjunctive medication used before ESWL patients were divided into control group and medication group (with ketochromate tromethamine 30 mg and phloroglucinol 80 mg before ESWL). Primary endpoint is the clearance rate of ureteral calculi after ESWL, secondary endpoint are the other outcomes and drug allergy. There were 138 cases in control group [117 were males and mean age (42±13) years]. Meanwhile, there were 137 cases in medication group [118 were males and mean age (42±12) years]. The clearance rate of ureteral calculi at 24 h (67.88% vs 48.55%, P=0.001)、one week (76.64% vs 57.97%, P=0.001) and four weeks (89.05% vs 76.08%, P=0.005)after ESWL in medication group were significant higher than that in control group. There was a significant difference in the VAS score of pain scale after ESWL (1.77±0.80 vs 2.06±1.04, P=0.012) and re-ESWL rate (8.03% vs 17.39%,P=0.02) between two groups, but no difference with gross hematuria in 6 h after ESWL and drug allergy. Conclusions combination use of ketochromate tromethamine and phloroglucinol significantly improve early expulsion of ureteral calculi after ESWL in patients with distal ureteral calculi, with no side effect.


Subject(s)
Drug Hypersensitivity , Lithotripsy , Ureteral Calculi , Male , Humans , Adult , Middle Aged , Female , Ureteral Calculi/therapy , Retrospective Studies , Tromethamine , Lithotripsy/adverse effects , Drug Hypersensitivity/etiology
2.
Zhonghua Xue Ye Xue Za Zhi ; 38(7): 602-606, 2017 Jul 14.
Article in Chinese | MEDLINE | ID: mdl-28810329

ABSTRACT

Objective: To describe the distribution and drug resistance of pathogens at hematology department of Jiangsu Province from 2014 to 2015 to provide reference for empirical anti-infection treatment. Methods: Pathogens were from hematology department of 26 tertiary hospitals in Jiangsu Province from 2014 to 2015. Antimicrobial susceptibility testing was carried out according to a unified protocol using Kirby-Bauer method or agar dilution method. Collection of drug susceptibility results and corresponding patient data were analyzed. Results: The separated pathogens amounted to 4 306. Gram-negative bacteria accounted for 64.26%, while the proportions of gram-positive bacteria and funguses were 26.99% and 8.75% respectively. Common gram-negative bacteria were Escherichia coli (20.48%) , Klebsiella pneumonia (15.40%) , Pseudomonas aeruginosa (8.50%) , Acinetobacter baumannii (5.04%) and Stenotropho-monas maltophilia (3.41%) respectively. CRE amounted to 123 (6.68%) . Common gram-positive bacteria were Staphylococcus aureus (4.92%) , Staphylococcus hominis (4.88%) and Staphylococcus epidermidis (4.71%) respectively. Candida albicans were the main fungus which accounted for 5.43%. The rates of Escherichia coli and Klebsiella pneumonia resistant to carbapenems were 3.5%-6.1% and 5.0%-6.3% respectively. The rates of Pseudomonas aeruginosa resistant to tobramycin and amikacin were 3.2% and 3.3% respectively. The resistant rates of Acinetobacter baumannii towards tobramycin and cefoperazone/sulbactam were both 19.2%. The rates of Stenotrophomonas maltophilia resistant to minocycline and sulfamethoxazole were 3.5% and 9.3% respectively. The rates of Staphylococcus aureus, Enterococcus faecium and Enterococcus faecalis resistant wards vancomycin were 0, 6.4% and 1.4% respectively; also, the rates of them resistant to linezolid were 1.2%, 0 and 1.6% respectively; in addition, the rates of them resistant to teicoplanin were 2.8%, 14.3% and 8.0% respectively. Furthermore, MRSA accounted for 39.15% (83/212) . Conclusions: Pathogens were mainly gram-negative bacteria. CRE accounted for 6.68%. The rates of Escherichia coli and Klebsiella pneumonia resistant to carbapenems were lower compared with other antibacterial agents. The rates of gram-positive bacteria resistant to vancomycin, linezolid and teicoplanin were still low. MRSA accounted for 39.15%.


Subject(s)
Drug Resistance, Bacterial , Anti-Bacterial Agents , Gram-Negative Bacteria , Humans , Microbial Sensitivity Tests , Retrospective Studies
3.
Br J Anaesth ; 115(5): 752-60, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26475803

ABSTRACT

BACKGROUND: We tested the hypothesis that developmental effects of repeated neonatal exposure to sevoflurane in rats are exacerbated by stressful experiences received later in life. METHODS: Sprague-Dawley male rats received sequential exposures to 3% sevoflurane for two h on postnatal days (P) six, seven, and eight. After weaning at P21, rats were housed either in pairs in an enriched environment (EE) or singly in an enrichment-deprived environment (an adverse environment, AE). The hippocampal concentrations of brain-derived neurotrophic factor (BDNF), and synaptic markers were assessed at P8 and P53. The dentate gyrus neural progenitor proliferation was evaluated at P11 and P53 after administration of bromodeoyuridine (BrdU) at P8 to P10 and at P22 to P27, respectively. Neurobehavioural evaluations were performed at P49 to P53. RESULTS: Repeated sevoflurane exposure acutely reduced concentrations of BDNF, synaptic markers and neural progenitor proliferation. The sevoflurane group housed in the AE conditions (sevoflurane+AE) had decreased concentrations of BDNF and synaptic markers, and survival of new granule cells and impaired cognitive function compared with the control+AE, control+EE, and sevoflurane+EE groups. The neurobehavioural parameters in the sevoflurane+EE and control+EE groups were similar. CONCLUSIONS: Neurocognitive abnormalities induced by repeated neonatal exposure to sevoflurane can be aggravated by stressful conditions such as social isolation and enrichment deprivation.


Subject(s)
Anesthetics, Inhalation/toxicity , Behavior, Animal/drug effects , Cognition Disorders/etiology , Methyl Ethers/toxicity , Social Isolation/psychology , Animals , Animals, Newborn , Brain-Derived Neurotrophic Factor/metabolism , Cell Proliferation/drug effects , Cognition Disorders/metabolism , Conditioning, Classical/drug effects , Dentate Gyrus/drug effects , Dentate Gyrus/pathology , Hippocampus/drug effects , Hippocampus/metabolism , Male , Neural Stem Cells/drug effects , Neural Stem Cells/pathology , Rats, Sprague-Dawley , Sevoflurane , Social Environment
6.
Article in Chinese | MEDLINE | ID: mdl-2208619

ABSTRACT

340 cases of hookworm infection, 196 cases of ascariasis and 178 cases of trichuriasis were treated with an anthelmintic, oxibendazole, 15mg/kg.d x 3d; 102, 70 and 66 cases of respective infections were treated with pyrantel 10mg/kg.d x 3d and 108, 74 and 63 cases took placebo for comparison and as control under double-blind observations. Re-examinations of the stool were performed after the treatment. Among the cases treated with oxibendazole, the egg negative conversion rates of hookworm, Ascaris and Trichuris were 70.3-80.6%, 92.5-97.8 and 67.0-71.0% respectively. The egg reduction rates of hookworm were 98.1-98.6%. The larval negative conversion rates of Ancylostoma duodenale and Necator americanus were 77.7 and 83.2% respectively. Among the cases treated with pyrantel, the egg negative conversion rates of the three above mentioned parasites were 73.5, 90.0 and 28.8% respectively. The egg reduction rate of hookworm was 98.8%. Among the cases treated with placebo, the egg negative conversion rates of the three above mentioned parasites were 6.5, 29.7 and 7.9%. No marked adverse reactions were observed by clinical and laboratory examinations.


Subject(s)
Anthelmintics/therapeutic use , Ascariasis/drug therapy , Ascaris , Benzimidazoles/therapeutic use , Trichuriasis/drug therapy , Trichuris , Animals , Benzimidazoles/adverse effects , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...